Correlation of Lactic Dehydrogenase Isoenzymes in Prostatic Tissue with Serum Acid Phosphatase, Digital Examination and Histological Diagnosis

Clark, Samuel S.; Srinivasan, V.

doi:10.1016/s0022-5347(17)60448-8

Cited by 6 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While several authors report special LDH ratio (LDH 5/1) patterns, which should be significant for PCA [11], others found this test to be of no value in the initial clinical diagnosis [12].…”

Section: Introductionmentioning

confidence: 99%

Prostate-Specific Antigen in Prostatic Carcinoma

Jurincic¹,

Pixberg²,

Gasser³

et al. 1990

Urol Int

View full text Add to dashboard Cite

To evaluate the clinical and prognostic value of prostate-specific antigen (PSA) for the detection of tumor and tumor growth after therapy, 520 sera from 246 patients with prostatic carcinoma, 990 sera from patients with BPH, and 1,488 sera from patients with other urological diseases were analyzed. The values ranged from 0.1 to 1,828.9 ng/ml. 51 % of all values were about 2.5 ng/ml, and 76.8% of all values about 10 ng/ml. The commercial recommendation for the cutoff values is 2.5 ng/ml (IBL, FRG). In patients with benign prostatic hypertrophy this cutoff means 61% false-positive results, which makes the test highly sensitive but unspecific. In prostatic carcinoma patients this borderline means a false-negative result in 9.75% (24 of 246). By determinating the cutoff at 10 ng/ml in our series, a false-negative result appeared in 14.6 %. Therefore a plea is made for the 10-ng/ml cutoff. In follow-up studies a marked decline in PSA values after transurethral resection or antiandrogen therapy (orchiectomy/Zoladex® /ICI/flutamide, Essex). Generally, the greater the PSA levels the more advanced the stage of disease. These data suggest that PSA may be a useful adjuvant marker for monitoring tumor growth in patients with regionally confined tumor.

show abstract

Section: Introductionmentioning

confidence: 99%

Prostate-Specific Antigen in Prostatic Carcinoma

Jurincic¹,

Pixberg²,

Gasser³

et al. 1990

Urol Int

View full text Add to dashboard Cite

show abstract

The diagnosis of prostatic cancer

Murphy¹

1976

Cancer

View full text Add to dashboard Cite

The diagnosis and detection of genitourinary cancer covers a broad range of physical signs and instrumental observations which are not necessarily diagnostic. The primary diagnosis in most entities remains dependent upon histologic confirmation. Adenocarcinoma of the prostate is the most common, and at times, most difficult urogenital cancer to diagnose and detect. Many newer techniques today are designed to evaluate the stage of disease, and to detect heretofore occult metastatic foci. Immunologic assays may be of future prognostic value.

show abstract

Overview of past and current philosophy of prostatic cancer

1980

View full text Add to dashboard Cite

Carcinoma of the prostate is the second most common cancer in men, yet no significant change in overall survival has occurred since the original description of the results of castration by Huggins and Hodges. Many important questions about the disease remain unanswered. The cause of prostatic cancer is unknown, and few specific environmental or viral agents have been linked with the tumor. Increased recognition of the importance of frequent digitial rectal examination has resulted in more tumors being diagnosed in early stages. Developments in sonography suggest that it may be useful in detecting the presence of prostatic cancer and whether extraprostatic extension has occurred. Recent inprovements in the sensitivity of prostatic acid phosphatase assays have been made, but their use as a screening tool remains limited. In patients with clinical stage B lesions that are microscopically confined to the prostate, treatment by radical prostatectomy appears to confer greatest survival. The exact role of radiotherapy remains to be defined. However, when the tumor extends beyond the prostate and is localized to the pelvis, external beam ro interstitial radiation is appropriate. Pelvic lymphadenectomy has significant morbidity, but less invasive methods of pelvic nodal evaluation are less accurate. Lymphadenectomy has not been shown to have any therapeutic effect. Whether hormonal therapy improves survival needs further investigation, and efforts must continue to develop means of predicting hormonal responsiveness. Those patients unlikely to respond to hormonal therapy should be treated with early chemotherapy.

show abstract

Correlation of Lactic Dehydrogenase Isoenzymes in Prostatic Tissue with Serum Acid Phosphatase, Digital Examination and Histological Diagnosis

Cited by 6 publications

References 16 publications

Prostate-Specific Antigen in Prostatic Carcinoma

Prostate-Specific Antigen in Prostatic Carcinoma

The diagnosis of prostatic cancer

Overview of past and current philosophy of prostatic cancer

Contact Info

Product

Resources

About